EX-10.110-Q·CIK 1434647·0001434647-26-000068

EX-10.1

View original filing on SEC EDGAR → ·  seen Aug 05, 2026, 17:23 EDT

Export to Cicero →


FILING DETAILS

Filer
ZEVRA THERAPEUTICS, INC.
Period of report
Jun 30, 2026
Filed
Aug 05, 2026
SEC file no.
001-36913
State of inc.
DE
SIC
2834
Location
BOSTON, MA

Exhibit 10.1

FIRST AMENDMENT

TO THE EMPLOYMENT AGREEMENT

This FIRST AMENDMENT (the “First Amendment”) to the Employment Agreement (the “Agreement”), between Zevra Therapeutics, Inc. (the “Company”) and Timothy Sangiovanni (the “Executive”) is made and entered into as of the last date of signature set forth below (the “First Amendment Effective Date”), by and between the Company and the Executive;

WITNESSETH:

WHEREAS, the Company and the Executive entered into the Agreement effective February 1, 2017; and

WHEREAS, the Company and the Executive now desire to amend the Agreement to amend provisions relating to accelerated vesting of outstanding equity granted on or after the First Amendment Effective Date upon the occurrence of a termination without “Cause” or for “Good Reason” (each as defined in the Agreement);

NOW, THEREFORE, the Company and the Executive, effective as of the date set forth above, do hereby amend the Agreement as follows:

1.

Section 4(E)(1)(d) of the Agreement shall be deleted in its entirety and replaced with the following:

“(d) The vesting of each outstanding equity award granted to Executive will accelerate so that such awards will be fully vested as of the Date of Termination. If any equity awards vest based on the attainment of performance goals, the performance goals will be deemed to have beenmet as of the Date of Termination, unless such greater amount of vesting is provided for in the applicable award agreements. Notwithstanding the foregoing, this Subsection (d) shall not apply with respect to any equity awards granted on or after the First Amendment Effective Date, and such awards shall be subject to vesting, if at all, pursuant to the terms of the applicable award agreement.”

2.

Except as specifically amended hereby, the Agreement shall remain in full force and effect as prior to this First Amendment.

IN WITNESS WHEREOF, the parties have caused this First Amendment to be executed as of the First Amendment Effective Date.

ZEVRA THERAPEUTICS, INC.

By: /s/ Rahsaan Thompson

Name: Rahsaan Thompson

Title: Chief Legal Officer, Secretary and Compliance Officer

Date: 14-May-2026


Exhibit 10.1

/s/Timothy Sangiovanni

Timothy Sangiovanni

Date: 15-May-2026

← Back to all agreements